Status | Study |
Completed |
Study Name: Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 Condition: Adult T-cell Leukemia-Lymphoma Date: 2010-07-30 Interventions: Drug: VCAP/AMP/VECP(mLSG15) VC |
Completed |
Study Name: A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma Condition: Adult T-cell Leukemia-Lymphoma Peripheral T-cell Lymphoma Date: 2010-07-22 Interventions: Drug: Lenalidomide Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily o |
Completed |
Study Name: EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma Condition: Leukemia-Lymphoma, Adult T-Cell Date: 2009-10-19 Interventions: Drug: Bortezomib Other Name: V |
Active, not recruiting |
Study Name: Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia Condition: Adult T-Cell Leukemia (ATL) Date: 2009-06-17 Interventions: Drug: LMB-2 Begin with 30 mcg/ |
Completed |
Study Name: Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma Condition: Adult T-cell Leukemia-lymphoma Date: 2009-06-09 Interventions: Biological: KW-0761 KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at |
Terminated |
Study Name: Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma Condition: Lymphoma Precancerous/Nonmalignant Condition Date: 2009-02-28 Interventions: Biological: PEG-interferon alfa-2b |
Completed |
Study Name: Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1 Condition: Human T-Lymphoma Virus Type I Date: 2006-06-19 |
Completed |
Study Name: A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL) Condition: Adult T-cell Leukemia Lymphoma Date: 2005-09-01 Interventions: Drug: VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis |
Completed |
Study Name: Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia Condition: Leukemia, Adult T-Cell Date: 2005-07-07 Interventions: Biological: Denileukin diftitox (Ontak) Patients will be treated with Denileukin Diftitox 9 mcg/kg/d int |
Completed |
Study Name: Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia Condition: Leukemia, T-Cell Date: 2004-11-03 Interventions: Drug: forodesine hydrochloride (BCX-1777) |